AKT1 and ovarian carcinoma: PTEN might reverse the chemoresistance of human ovarian cancer cells to cisplatin through inactivation of the PI3K/AKT cell survival pathway and may serve as a potential molecular target for the treatment of chemoresistant ovarian cancer [51].